Phase II trial of the phosphatidyinositol-3 kinase (PLIK) inhibitor buparlisib (BKM120) in recurrent glioblastoma

被引：4
|
作者：
Wen, Patrick Y.
Yung, W. K. Alfred
Mellinghoff, Ingo K.
Ramkissoon, Shakti
Alexander, Brian Michael
Rinne, Mikael L.
Colman, Howard
Omura, Antonio MarcIllo Paduia
DeAngelis, Lisa Marie
Gilbert, Mark R.
De Groot, John Frederick
Cloughesy, Timothy Francis
Chi, Andrew S.
Lee, Eudocia Quant
Nayak, Lakshmi
Batchelor, Tracy
Chang, Susan Marina
Prados, Michael
Reardon, David A.
Ligon, Keith L.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Utah Huntsman Canc Inst, Salt Lake City, UT USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Boston Childrens Hosp, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2019
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
    Ma, Cynthia X.
    Luo, Jingqin
    Naughton, Michael
    Ademuyiwa, Foluso
    Suresh, Rama
    Griffith, Malachi
    Griffith, Obi L.
    Skidmore, Zachary L.
    Spies, Nicholas C.
    Ramu, Avinash
    Trani, Lee
    Pluard, Timothy
    Nagaraj, Gayathri
    Thomas, Shana
    Guo, Zhanfang
    Hoog, Jeremy
    Han, Jing
    Mardis, Elaine
    Lockhart, Craig
    Ellis, Matthew J.
    CLINICAL CANCER RESEARCH, 2016, 22 (07) : 1583 - 1591
  • [22] Phase II study of the PI3K inhibitor BKM120 monotherapy in patients with advanced or recurrent endometrial carcinoma: ENDOPIK, GINECO Study.
    Heudel, Pierre-Etienne
    Fabbro, Michel
    Roemer-Becuwe, Celia
    Treilleux, Isabelle
    Kaminsky, Marie-Christine
    Arnaud, Antoine
    Joly, Florence
    Forestier, Sophie Roche
    Herve, Robert
    Ray-Coquard, Isabelle
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] A phase I dose-escalation study of buparlisib (BKM120), an oral pan-PI3K inhibitor, in Chinese patients with advanced solid tumors
    Zhang, L.
    Xu, B.
    Hazell, K.
    Gaur, A.
    Xu, J.
    Trandafir, L.
    Wu, Y. L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S186
  • [24] Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
    Anderson, Jennifer L.
    Park, Ann
    Akiyama, Ryan
    Tap, William D.
    Denny, Christopher T.
    Federman, Noah
    PLOS ONE, 2015, 10 (09):
  • [25] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Ana C. Garrido-Castro
    Cristina Saura
    Romualdo Barroso-Sousa
    Hao Guo
    Eva Ciruelos
    Begoña Bermejo
    Joaquin Gavilá
    Violeta Serra
    Aleix Prat
    Laia Paré
    Pamela Céliz
    Patricia Villagrasa
    Yisheng Li
    Jennifer Savoie
    Zhan Xu
    Carlos L. Arteaga
    Ian E. Krop
    David B. Solit
    Gordon B. Mills
    Lewis C. Cantley
    Eric P. Winer
    Nancy U. Lin
    Jordi Rodon
    Breast Cancer Research, 22
  • [26] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Garrido-Castro, Ana C.
    Saura, Cristina
    Barroso-Sousa, Romualdo
    Guo, Hao
    Ciruelos, Eva
    Bermejo, Begona
    Gavila, Joaquin
    Serra, Violeta
    Prat, Aleix
    Pare, Laia
    Celiz, Pamela
    Villagrasa, Patricia
    Li, Yisheng
    Savoie, Jennifer
    Xu, Zhan
    Arteaga, Carlos L.
    Krop, Ian E.
    Solit, David B.
    Mills, Gordon B.
    Cantley, Lewis C.
    Winer, Eric P.
    Lin, Nancy U.
    Rodon, Jordi
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [27] Phase 2 study of the pan-isoform PI3 kinase inhibitor BKM120 in metastatic urothelial carcinoma patients.
    Iyer, Gopa
    Tully, Christopher Michael
    Garcia-Grossman, Ilana Rebecca
    Scott, Sasinya N.
    Boyd, Mariel Elena
    Mccoy, Asia S.
    Berger, Michael F.
    Al-Ahmadie, Hikmat
    Solit, David B.
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [28] Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance
    Yu, Wenjun
    Chen, Yubao
    Xiang, Rufang
    Xu, Wenbin
    Wang, Yan
    Tong, Jia
    Zhang, Nan
    Wu, Yingli
    Yan, Hua
    LEUKEMIA & LYMPHOMA, 2017, 58 (02) : 428 - 437
  • [29] Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
    Matas-Cespedes, Alba
    Rodriguez, Vanina
    Kalko, Susana G.
    Vidal-Crespo, Anna
    Rosich, Laia
    Casserras, Teresa
    Balsas, Patricia
    Villamor, Neus
    Gine, Eva
    Campo, Elias
    Roue, Gael
    Lopez-Guillermo, Armando
    Colomer, Dolors
    Perez-Galan, Patricia
    CLINICAL CANCER RESEARCH, 2014, 20 (13) : 3458 - 3471
  • [30] Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group
    P-E Heudel
    M Fabbro
    C Roemer-Becuwe
    M C Kaminsky
    A Arnaud
    F Joly
    S Roche-Forestier
    J Meunier
    C Foa
    B You
    F Priou
    Y Tazi
    A Floquet
    F Selle
    D Berton-Rigaud
    A Lesoin
    E Kalbacher
    A Lortholary
    L Favier
    I Treilleux
    I Ray-Coquard
    British Journal of Cancer, 2017, 116 : 303 - 309
12345